256 related articles for article (PubMed ID: 12127665)
21. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
22. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
Longthorne PN
BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939141
[No Abstract] [Full Text] [Related]
23. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
Cardy P
BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142
[No Abstract] [Full Text] [Related]
24. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis].
Losy J
Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302
[TBL] [Abstract][Full Text] [Related]
25. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
[No Abstract] [Full Text] [Related]
27. [Report from the Satellite Symposium: Leading the way: outstanding efficacy of interferon beta-1b right from the start. Berlin, Germany, 06.24.2002].
Cendrowski W
Neurol Neurochir Pol; 2002; 36(6):1260-3. PubMed ID: 12715704
[No Abstract] [Full Text] [Related]
28. Nursing management of MS patients receiving interferon beta-1b therapy.
Costello K; Conway K
Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
[TBL] [Abstract][Full Text] [Related]
29. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
30. Interferon beta in multiple sclerosis.
Richards RG
BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
[No Abstract] [Full Text] [Related]
31. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease.
Chellingsworth M
BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939140
[No Abstract] [Full Text] [Related]
32. Contemporary immunomodulatory therapy for multiple sclerosis.
Rudick RA
J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
[TBL] [Abstract][Full Text] [Related]
33. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Kappos L
Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
[No Abstract] [Full Text] [Related]
34. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
35. Why interferon beta 1b was licensed is a mystery.
Harvey P
BMJ; 1996 Aug; 313(7052):297-8. PubMed ID: 8704553
[No Abstract] [Full Text] [Related]
36. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
Bykova OV; Kuzenkova LM; Maslova OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
[TBL] [Abstract][Full Text] [Related]
37. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
38. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
39. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
Blake G; Murphy S
Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
[No Abstract] [Full Text] [Related]
40. Meningioma growth during interferon beta-1A treatment for multiple sclerosis.
Gama HP; Rocha AJ; Silva CJ; Mendes MF; Veiga JC; Lancellotti CL; Andrade VP; Tilbery CP
Arq Neuropsiquiatr; 2008 Jun; 66(2B):402-4. PubMed ID: 18641881
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
